Editas Medicine, Inc. Common Stock
EDIT Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
EDIT Income Statement
EDIT Balance Sheet
EDIT Cash Flow
Recent trades of EDIT by members of U.S. Congress
EDIT Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
EDIT Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
EDIT Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by EDIT's directors and management
Government lobbying spending instances
-
$10,000 May 06, 2020 Issue: Health Issues Medicare/Medicaid
-
$40,000 Apr 26, 2020 Issue: Health Issues
-
$50,000 Apr 20, 2020 Issue: Medicare/Medicaid Health Issues
-
$40,000 Feb 03, 2020 Issue: Health Issues
-
$50,000 Jan 21, 2020 Issue: Health Issues Medicare/Medicaid
-
$40,000 Nov 01, 2019 Issue: Health Issues
-
$50,000 Oct 21, 2019 Issue: Health Issues Medicare/Medicaid
-
$40,000 Aug 06, 2019 Issue: Health Issues
-
$50,000 Jul 22, 2019 Issue: Health Issues Medicare/Medicaid
-
$40,000 May 03, 2019 Issue: Health Issues
-
$50,000 Apr 19, 2019 Issue: Health Issues Medicare/Medicaid
-
$40,000 Jan 23, 2019 Issue: Health Issues
-
$45,000 Jan 18, 2019 Issue: Health Issues Medicare/Medicaid
-
$40,000 Oct 25, 2018 Issue: Health Issues
-
$45,000 Oct 18, 2018 Issue: Medicare/Medicaid Health Issues
-
$40,000 Aug 01, 2018 Issue: Health Issues
-
$45,000 Jul 20, 2018 Issue: Health Issues Medicare/Medicaid
-
$40,000 Apr 20, 2018 Issue: Health Issues
-
$45,000 Apr 20, 2018 Issue: Medicare/Medicaid Health Issues
-
$45,000 Jan 22, 2018 Issue: Health Issues Taxation/Internal Revenue Code
-
$40,000 Jan 22, 2018 Issue: Health Issues
-
$40,000 Oct 20, 2017 Issue: Health Issues
-
$45,000 Oct 19, 2017 Issue: Health Issues Defense
-
$15,000 Jul 20, 2017 Issue: Health Issues
-
$40,000 Jul 19, 2017 Issue: Health Issues
-
$40,000 Apr 19, 2017 Issue: Health Issues
-
$50,000 Jan 23, 2017 Issue: Health Issues
-
$60,000 Oct 19, 2016 Issue: Health Issues
-
$40,000 Jul 21, 2016 Issue: Health Issues
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Methods of assessing nuclease cleavage Oct. 08, 2024
-
Patent Title: Cas9 fusion molecules, gene editing systems, and methods of use thereof Jul. 30, 2024
-
Patent Title: Systems and methods for the treatment of hemoglobinopathies Jul. 09, 2024
-
Patent Title: Crispr/rna-guided nuclease systems and methods Apr. 23, 2024
-
Patent Title: Crispr/cas-related methods and compositions for improving transplantation Feb. 27, 2024
-
Patent Title: Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites Jan. 09, 2024
-
Patent Title: Systems and methods for the treatment of hemoglobinopathies Dec. 26, 2023
-
Patent Title: Crispr/cas-related methods and compositions for treating herpes simplex virus Dec. 05, 2023
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Jul. 04, 2023
-
Patent Title: Methods for improving crispr/cas-mediated genome-editing Jun. 20, 2023
-
Patent Title: Use of exonucleases to improve crispr/cas-mediated genome editing Jun. 06, 2023
-
Patent Title: Genome editing systems comprising repair-modulating enzyme molecules and methods of their use Mar. 07, 2023
-
Patent Title: Compositions and methods for treating cep290 associated disease Jan. 31, 2023
-
Patent Title: Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency Nov. 29, 2022
-
Patent Title: Methods and systems for analyzing guide rna molecules Nov. 15, 2022
-
Patent Title: Crispr-related methods and compositions with governing grnas Jul. 19, 2022
-
Patent Title: Optimized crispr/cas9 systems and methods for gene editing in stem cells Jul. 19, 2022
-
Patent Title: Crispr/cas-related methods and compositions for treating herpes simplex virus Jul. 19, 2022
-
Patent Title: Compositions and methods for treating cep290-associated disease May. 24, 2022
-
Patent Title: Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) Mar. 08, 2022
-
Patent Title: Crispr/cas-related methods and compositions for treating sickle cell disease Feb. 08, 2022
-
Patent Title: Cas9 fusion molecules, gene editing systems, and methods of use thereof Feb. 01, 2022
-
Patent Title: Evaluation of cas9 molecule/guide rna molecule complexes Nov. 23, 2021
-
Patent Title: Compositions and methods for treating cep290-associated disease Oct. 12, 2021
-
Patent Title: Engineered cas9 nucleases Aug. 24, 2021
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Jun. 08, 2021
-
Patent Title: Crispr/cas-related methods and compositions for treating cystic fibrosis Jun. 08, 2021
-
Patent Title: Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa Jun. 08, 2021
-
Patent Title: Crispr/cas-related methods and compositions for treating herpes simplex virus May. 11, 2021
-
Patent Title: Crispr-related methods and compositions with governing grnas May. 05, 2020
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Dec. 03, 2019
-
Patent Title: Engineered cas9 nucleases Oct. 01, 2019
-
Patent Title: Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) Apr. 09, 2019
-
Patent Title: Crispr-related methods and compositions with governing grnas Jan. 29, 2019
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna Jun. 26, 2018
-
Patent Title: Systems and methods for one-shot guide rna (ogrna) targeting of endogenous and source dna May. 08, 2018
-
Patent Title: Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) Apr. 10, 2018
-
Patent Title: Crispr-related methods and compositions with governing grnas Dec. 05, 2017
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of EDIT in WallStreetBets Daily Discussion
EDIT News
Recent insights relating to EDIT
CNBC Recommendations
Recent picks made for EDIT stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in EDIT
EDIT Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view EDIT Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More